Brief: Caribou Biosciences Says CB-010 ANTLER Phase 1 Trial Initial Dose Expansion Data And RP2D To Be Disclosed Q2 2024

Caribou Biosciences

07/01/2024 16:03

Jan 7 (Reuters) - Caribou Biosciences Inc  CRBU.O :
    * CARIBOU BIOSCIENCES APPOINTS TIM KELLY AS CHIEF TECHNOLOGY
OFFICER AND HIGHLIGHTS MULTIPLE CLINICAL CATALYSTS EXPECTED IN
2024
    * CB-010 ANTLER PHASE 1 TRIAL INITIAL DOSE EXPANSION DATA
AND RP2D
TO BE DISCLOSED Q2 2024
    * PLANS TO INITIATE PIVOTAL PHASE 3 TRIAL IN 2L LBCL BY YE
2024
    * CB-011 CAMMOUFLAGE PHASE 1 TRIAL ENROLLING PATIENTS AT
DOSE
LEVEL 3; INITIAL DOSE ESCALATION DATA IN R/R MM EXPECTED BY YE
2024
    * CB-012 AMPLIFY PHASE 1 TRIAL FIRST SITES ACTIVE; TRIAL
INITIATION IN R/R AML EXPECTED H1 2024

Source text for Eikon:  ID:nGNX3JQqr0 
Further company coverage:  CRBU.O 

 ((Reuters.Briefs@thomsonreuters.com;))